Idorsia Starts Phase 3 Lucerastat Study, Agrees Nxera Co-Development
Idorsia said it has initiated a pivotal Phase 3 study of lucerastat in Fabry disease and entered a co-development and commercialization agreement with Nxera.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.